The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

Metabolism: Clinical and Experimental

Volumn 65, Issue 2, 2016, Pages 114-123

  Kern, Matthias ^a   Klöting, Nora ^a   Mark, Michael ^b   Mayoux, Eric ^b   Klein, Thomas ^b   Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

DPP 4 inhibitor; Glycemic control; Insulin resistance; SGLT2 inhibitor

Indexed keywords

ACYL COENZYME A DESATURASE; EMPAGLIFLOZIN; F4/80 PROTEIN; FAS ANTIGEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; MESSENGER RNA; PROTEIN; PROTEIN TYROSINE PHOSPHATASE 1B; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DB/DB MOUSE; FAT CONTENT; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GONAD; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KIDNEY; LIPID METABOLISM; LIVER; LIVER METABOLISM; LONG TERM CARE; MONOTHERAPY; MOUSE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; TISSUES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WATER TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; PANCREAS ISLET BETA CELL;

ANIMALS; BENZHYDRYL COMPOUNDS; FEMALE; GLUCOSE; GLUCOSIDES; GLYCOSIDES; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LINAGLIPTIN; LIPID METABOLISM; MICE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84959511891     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.10.010     Document Type: Article

References (37)

1. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, and et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 1 2012 83 90
2. L.J. Scott Empagliflozin: a review of its use in patients with type 2 diabetes mellitus Drugs 74 15 2014 1769 1784
3. L. Thomas, R. Grempler, M. Eckhardt, F. Himmelsbach, A. Sauer, T. Klein, and et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats Diabetes Obes Metab 14 1 2012 94 96
4. G. Luippold, T. Klein, M. Mark, and R. Grempler Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus Diabetes Obes Metab 14 7 2012 601 607
5. C.F. Deacon, and J.J. Holst Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin Investig Drugs 19 1 2010 133 140
6. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J Pharmacol Exp Ther 325 1 2008 175 182
7. H. Fuchs, J.P. Tillement, S. Urien, A. Greischel, and W. Roth Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans J Pharm Pharmacol 61 1 2009 55 62
8. S. Blech, E. Ludwig-Schwellinger, E.U. Gräfe-Mody, B. Withopf, and K. Wagner The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab Dispos 38 4 2010 667 678
9. T. Heise, E.U. Graefe-Mody, S. Hüttner, A. Ring, D. Trommeshauser, and K.A. Dugi Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 11 8 2009 786 794
10. M. Kern, N. Klöting, H.G. Niessen, L. Thomas, D. Stiller, M. Mark, and et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity PLoS One 7 6 2012 e38744
11. E.G. Bligh, and W.J. Dyer A rapid method of total lipid extraction and purification Can J Biochem Physiol 37 8 1959 911 917
12. R.K. Ghosh, S.M. Ghosh, S. Chawla, and S.A. Jasdanwala SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus J Clin Pharmacol 52 4 2012 457 463
13. M.A. Abdul-Ghani, L. Norton, and R.A. DeFronzo Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus Curr Diab Rep 12 3 2012 230 238
14. E. Ferrannini Learning from glycosuria Diabetes 60 3 2011 695 696
15. M.A. Abdul-Ghani, L. Norton, and R.A. Defronzo Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 4 2011 515 531
16. H. Chasis, N. Jolliffe, and H.W. Smith The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man J Clin Invest 12 6 1933 1083 1090
17. A. Kashiwagi, Y. Takinami, K. Kazuta, S. Yoshida, A. Utsuno, and I. Nagase Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study Diabetologia 54 Suppl. 1 2011 S68 S69
18. Y. Seino, T. Sasaki, A. Fukatsu, Y. Samukawa, S. Sakai, and T. Watanabe TS-071, a novel and selective SGLT2 inhibitor, improved glycemic control and decreased body weight in 12-week study of Japanese patients with type 2 diabetes mellitus Diabetes 60 Suppl. 1 2011 A274
19. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, and et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 6 2008 1723 1729
20. S. Nomura, S. Sakamaki, M. Hongu, E. Kawanishi, Y. Koga, T. Sakamoto, and et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J Med Chem 53 17 2010 6355 6360
21. B.B. Kahn, G.I. Shulman, R.A. DeFronzo, S.W. Cushman, and L. Rossetti Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression J Clin Invest 87 2 1991 561 570
22. L. Rossetti, D. Smith, G.I. Shulman, D. Papachristou, and R.A. DeFronzo Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats J Clin Invest 79 5 1987 1510 1515
23. R. Santer, M. Kinner, C.L. Lassen, R. Schneppenheim, P. Eggert, M. Bald, and et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 11 2003 2873 2882
24. J. Rosenstock, L.J. Seman, A. Jelaska, S. Hantel, S. Pinnetti, T. Hach, and et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes Metab 15 12 2013 1154 1160
25. E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, T. Heise, and et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 124 2 2014 499 508
26. A. Merovci, C. Solis-Herrera, G. Daniele, R. Eldor, T.V. Fiorentino, D. Tripathy, and et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 124 2 2014 509 514
27. L.J. Scott Linagliptin: in type 2 diabetes mellitus Drugs 71 5 2011 611 624
28. S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, and K.A. Dugi Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes Obes Metab 13 3 2011 258 267
29. R. Gomis, R.M. Espadero, R. Jones, H.J. Woerle, and K.A. Dugi Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 13 7 2011 653 661
30. L. Chen, T. Klein, and P.S. Leung Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice Curr Mol Med 12 8 2012 995 1004
31. M.J. Jurczak, H.Y. Lee, A.L. Birkenfeld, F.R. Jornayvaz, D.W. Frederick, R.L. Pongratz, and et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function Diabetes 60 3 2011 890 898
32. Y. Sharkovska, C. Reichetzeder, M. Alter, O. Tsuprykov, S. Bachmann, T. Secher, and et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy J Hypertens 32 11 2014 2211 2223
33. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikuta, and I. Tanaka Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition Metabolism 52 1 2003 81 86
34. S. Roy, V. Khanna, S. Mittra, A. Dhar, S. Singh, D.C. Mahajan, and et al. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice Life Sci 81 1 2007 72 79
35. D.R. Powell, C.M. DaCosta, M. Smith, D. Doree, A. Harris, L. Buhring, and et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models J Pharmacol Exp Ther 350 2 2014 232 242
36. A. González-Rodríguez, J.A. Más-Gutierrez, M. Mirasierra, A. Fernandez-Pérez, Y.J. Lee, H.J. Ko, and et al. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging Aging Cell 11 2 2012 284 296
37. N. Sachithanandan, B.C. Fam, S. Fynch, N. Dzamko, M.J. Watt, S. Wormald, and et al. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity Hepatology 52 5 2010 1632 1642